P450-BM3 variants with improved activity
US-10982197-B2 · Apr 20, 2021 · US
US11279917B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11279917-B2 |
| Application number | US-202015931310-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2020 |
| Priority date | Jul 9, 2014 |
| Publication date | Mar 22, 2022 |
| Grant date | Mar 22, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
Opening claim text (preview).
What is claimed is: 1. A recombinant cytochrome P450-BM3 variant having cytochrome P450-BM3 activity and comprising the amino acid sequence of SEQ ID NO: 48. 2. The recombinant cytochrome P450-BM3 variant of claim 1 , wherein said variant oxidizes at least three organic substrates. 3. The recombinant cytochrome P450-BM3 variant of claim 2 , wherein the at least three organic substrates are selected from the group consisting of nifedipine, propranolol, verapamil, and diclofenac. 4. An isolated polynucleotide comprising a polynucleotide sequence encoding the recombinant cytochrome P450-BM3 variant of claim 1 . 5. The isolated polynucleotide of claim 4 , wherein said polynucleotide comprises the polynucleotide sequence of SEQ ID NO: 47. 6. An expression vector comprising the polynucleotide of claim 4 . 7. The vector of claim 6 , wherein said polynucleotide sequence is operably linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell. 8. The vector of claim 7 , wherein said host cell is a prokaryotic or eukaryotic cell. 9. The vector of claim 8 , wherein said host cell is a prokaryotic cell. 10. The vector of claim 8 , wherein said host cell is E. coli. 11. An isolated host cell comprising the vector of claim 6 . 12. A method for producing at least one recombinant cytochrome P450-BM3 variant comprising culturing the host cell of claim 11 under conditions such that the recombinant cytochrome P450-BM3 variant is produced. 13. The method of claim 12 , further comprising the step of recovering said at least one recombinant cytochrome P450-BM3 variant.
Amines; Imines · CPC title
NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase · CPC title
acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title
Cytochromes · CPC title
NADPH-cytochrome P450 reductase (1.6.2.4) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.